Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000571391 | SCV000662481 | pathogenic | Hereditary cancer-predisposing syndrome | 2017-09-28 | criteria provided, single submitter | clinical testing | The c.643delG pathogenic mutation (also known as p.V215*), located in coding exon 4 of the MSH6 gene, results from a deletion of one nucleotide at nucleotide position 643. This changes the amino acid from a valine to a stop codon within coding exon 4. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV003593981 | SCV004365313 | pathogenic | Hereditary nonpolyposis colorectal neoplasms | 2023-12-15 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Val215*) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with ovarian cancer (PMID: 28888541). ClinVar contains an entry for this variant (Variation ID: 479909). For these reasons, this variant has been classified as Pathogenic. |
CZECANCA consortium | RCV003128159 | SCV003804337 | pathogenic | Endometrial carcinoma | 2023-02-21 | no assertion criteria provided | clinical testing |